Atlas Trials

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

Clinical trial NCT02736266 · COMPLETED

Trial details

NCT number
NCT02736266
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial Bladder Carcinoma
Start date
2017-02-27
Primary completion
2018-10-20
Enrollment
174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.